Science – A life fully lived: Joe Sodroski wins the 2006 Retrovirology Prize by Lever, Andrew ML
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Retrovirology
Open Access Commentary
Science – A life fully lived: Joe Sodroski wins the 2006 Retrovirology 
Prize
Andrew ML Lever*
Address: Department of Medicine, University of Cambridge, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK
Email: Andrew ML Lever* - amll1@mole.bio.cam.ac.uk
* Corresponding author    
Abstract
The 2006 M Jeang Retrovirology Prize for HIV research has been awarded to Dr Joe Sodroski
Interview
In 2005 thanks to the generosity of Ming K. Jeang Foun-
dation, an educational foundation based in Houston,
Texas, the M Jeang Retrovirology prize was inaugurated
[1]. The award goes to a scientist in mid career who in the
opinion of the panel of judges [2] has, from the list of
nominations, made the most significant contribution to
the field. Awards for HIV related and non HIV related
research alternate yearly. Last year's winner was Stephen
Goff [3]. This year's winner of the Retrovirology Prize for
work in the HIV field has been won by Joseph Sodroski
(Fig 1).
Dr. Sodroski is Professor of Pathology at the Dana-Farber
Cancer Institute, Harvard Medical School and Professor of
Immunology and Infectious Diseases at Harvard School
of Public Health. Working in the laboratory of Dr. Wil-
liam Haseltine, initially with Dr. Craig Rosen, Dr.
Sodroski first demonstrated that HTLV-1 and HIV
encoded transactivating proteins Tax and Tat, respectively.
Dr. Sodroski also identified the Rev gene, which controls
the switch from early to late stages in the replication cycle
of HIV. He then studied the molecular and structural biol-
ogy and pathological effects of the HIV envelope glyco-
proteins. This culminated in the first X-ray crystal
structure of the external glycoprotein, gp120, work done
with Drs. Peter Kwong, Richard Wyatt and Wayne Hen-
drickson. Dr. Sodroski developed the simian-human
immunodeficiency virus (SHIV) model in monkeys, in
collaboration with Dr. Norman Letvin, and created the
first HIV-based vectors. Most recently his group identified
Trim5alpha as the restriction factor mediating post-entry
blocks to HIV in Old World monkeys. I took the opportu-
nity to ask Dr. Sodroski a wide-ranging set of questions
about science, HIV and research in general.
AMLL. Science is obviously a field in which you feel comforta-
ble and have succeeded yet your first degree is an MD. When
you originally chose Medicine would you have predicted that
this was the route that you would have followed or was there
something that drew you away from clinical work into research?
JS. My first love was science, but I was drawn to medicine
and the life sciences because of their complexity and obvi-
ous benefit to humanity. Medical school instilled in me a
life-long appreciation of the pathogenesis and treatment
of human disease. Ultimately, I realized that there were
only twenty-four hours in a day and decided to pursue
what I loved most.
AMLL. HIV was barely known about during your early train-
ing. What areas of research, if any, were you considering at that
time?
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JS. I began studying retroviruses because they were
involved in the activation of cellular oncogenes. My first
research in Bill Haseltine's lab studied the functional dif-
ferences between the viral v-fes oncogene and the cellular
proto-oncogene, c-fps/fes. Soon thereafter, it became clear
that human T-cell leukemia viruses (HTLVs) were induc-
ing leukemias/lymphomas in humans by a mechanism
that fundamentally differed from those employed by
either leukemia or sarcoma viruses in animals. Our stud-
ies revealed that HTLV encodes a transactivator protein,
Tax, that accounts for T-cell transformation by this virus.
When human immunodeficiency virus (HIV-1) was iso-
lated, we discovered an even more complex repertoire of
regulatory proteins. Over the years, the clinical impor-
tance of HIV-1 justified giving it an increasing share of my
attention.
AMLL. The beginning of your research career coincided with
the emergence of pathogenic human retroviruses HTLV-1 and
HIV so was it a case of being in the right place at the right time
or would you have deliberately moved towards the retroviral
area of research?
JS. Being in the right place at the right time was certainly
part of the story. Human retroviruses had just been dis-
covered, and Bill Haseltine's friendship with Bob Gallo
allowed us early access to key reagents. The other impor-
tant part of the story, however, was our mental prepared-
ness to discover novel aspects of these retroviruses and
how they induce disease. Chance favors only the prepared
mind, as Louis Pasteur phrased it.
AMLL. You worked closely with Bill Haseltine and a number of
other very well known scientific characters in the early days of
HIV research. What lessons did you learn from them?
JS. Bill Haseltine recognized the impact that HIV-1 would
have on global health long before the devastating nature
of the AIDS pandemic became apparent. So in those early
days, Bill and Bob Gallo and their colleagues, myself
included, shared a real sense of making an impact on the
history of the world with our work. In addition, Bill
taught me the power of rigorous thinking to reveal
answers and clarify murky research areas.
AMLL. You clearly have enormous enthusiasm for your work.
What is it about science that keeps you engaged and what
would you say to people considering a scientific career are the
biggest attractions and also the biggest problems to be prepared
for?
JS. A scientific life is fully lived, with its share of agony and
ecstasy. On occasion, scientists can enjoy the special priv-
ilege of learning something that no one else knows. Shar-
ing these experiences with the many dedicated and like-
minded colleagues that we train and collaborate with is
enormously fulfilling. In return for these privileges, scien-
tists live with the constant need to prove themselves capa-
ble of making the next novel discovery. Some of this
demand is self-imposed, but also derives from the require-
ment to attain funding.
AMLL. Scientific funding is always under fire for being inade-
quate. Do you think this reflects a lack of appreciation on the
part of funders or simple pragmatism? How would you persuade
the powers that be that more would be better?
JS. The American public and Congress generally are sup-
portive of medical research. Unfortunately, federal expen-
ditures in response to other crises have recently limited
the financial resources of the National Institutes of
Health. The impact of funding limitations will be slower
progress; moreover, some individuals that might other-
wise choose a scientific career will select other options.
This is unfortunate when the availability of so much novel
Dr Joe Sodroski winner of this year's Ming K Jeang award Figure 1
Dr Joe Sodroski winner of this year's Ming K Jeang award.Retrovirology 2006, 3:45 http://www.retrovirology.com/content/3/1/45
Page 3 of 4
(page number not for citation purposes)
information about genomes and proteomes presents
many opportunities for advancing the way medicine is
practiced.
AMLL. How do you feel that the research world has changed
since you began your work and is it for the better?
JS. Large-scale, empirical approaches to scientific discov-
ery have arrived and are well-suited to particular kinds of
research problems. There remains a need for hypothesis-
driven science from individuals as well. One of our future
challenges is educating sufficient numbers of high-quality
scientists suited to these different niches.
AMLL. If you had to guess how the HIV epidemic will evolve
globally what would your predictions be?
JS. The course of HIV-1 will be dictated by prevalence,
transmission rates, and death rates. HIV-1 prevalence has
probably achieved equilibrium in some countries and, in
other places where the virus has been introduced more
recently, prevalence will likely rise. I expect that, even in
the most optimistic scenario, HIV-1 infection and its
sequelae will remain a major health problem in the fore-
seeable future.
AMLL. Given that (as yet) there is no documented case of any-
one becoming infected with HIV and subsequently clearing the
virus how do you view the huge investment in vaccine
approaches to prevention of infection?
JS. Prevention of new HIV-1 infections is the key to chang-
ing the course of HIV-1 in the world. Traditionally, vac-
cines have been successful in preventing the transmission
of other viruses. Making a vaccine for a persistent virus
like HIV-1, however, involves many challenges. We don't
yet have a clear idea of what a successful HIV-1 vaccine
will look like. We'll need the concerted efforts of many
individuals and should be open to creative, non-tradi-
tional approaches to blocking HIV-1 transmission. Hope-
fully, novel ideas that translate into practical solutions
will emerge from the many collaborative groups that have
been organized and recently funded.
AMLL. As one of the earliest demonstrators of the practicality
of HIV and its family as gene vectors where do you think this
area of research will go and will it develop into mainstream
medicine?
JS. It's very likely that gene therapy will become the stand-
ard therapy for some conditions in the future. So far, len-
tivirus vectors have been useful as research tools. We'll
need to wait to see which gene delivery vectors emerge as
preferred clinical modalities.
AMLL. A mid-career prize implies that the next stage is late-
career. Will you be happy to continue (funding permitting) as
a research scientist through to retiring?
JS. I'm very happy in my present situation and would be
quite satisfied if I could continue to contribute to scien-
tific research until retirement.
AMLL. There is a famous piece of advice which is 'Never take
advice' but do you have any thoughts which you would pass on
to those starting in science which you would have appreciated
being told when you began?
JS. 1. Identify and pursue important research problems.
2. Trust your reason and intuition.
3. Persist.
4. Be objective.
5. Appreciate (not necessarily in this order) your students,
fellows, collaborators, spouse and family.Retrovirology 2006, 3:45 http://www.retrovirology.com/content/3/1/45
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